The current work examined the potential of making use of ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-kind (WT) breast tumor cells and in cells lacking useful p53 both by itself or in combination